Anixa Biosciences climbs after breast cancer vaccine moves to mid-stage trial

Shares of Anixa Biosciences ANIX.O rise 5.23% to $2.71

Biotech firm says it is advancing its experimental breast cancer vaccine for a mid-stage trial after positive results from an early-stage study

In the early-stage trial, the vaccine met the main goals of safety and tolerability, and triggered the planned immune response in 74% of participants - ANIX

Says it has signed a deal with contract manufacturer Cytovance Biologics to supply clinical material for the mid-stage trial

Adds that the vaccine targets alpha-lactalbumin, a protein that is usually seen in breast tissue during lactation but reappears in many breast cancers

Says the vaccine developed with Cleveland Clinic is designed to help the immune system attack cells carrying that protein and can have both treatment and prevention potential

ANIX shares rose over 34% in 2025